Volume 26, Number 9—September 2020
Research
Costs Associated with Nontuberculous Mycobacteria Infection, Ontario, Canada, 2001–2012
Table 5
Phase (no. patients) | Cost, CAD |
||
---|---|---|---|
Exposed persons | Unexposed persons | Attributable (95% CI) | |
Nontuberculous mycobacterial pulmonary disease | |||
Mean cost by phase | |||
Initial infection (6,187) | 1,189 | 238 | 951 (875–1,027) |
Subsequent care (6,187) | 653 | 227 | 428 (370–485) |
Continuous care (5,907) | 493 | 304 | 190 (153–227) |
Before death (2,204) |
5,662 |
4,183 |
1,479 (1,176–1,781) |
Nontuberculous mycobacterial pulmonary isolation | |||
Mean cost by phase | |||
Initial infection (7,693) | 807 | 193 | 614 (570–659) |
Subsequent care (7,693) | 412 | 192 | 220 (189–253) |
Continuous care (7,471) | 370 | 261 | 108 (85–130) |
Before death (1,963) | 4,692 | 3,843 | 850 (589–1,110) |
*Analysis excluded excluding persons with a history of lung cancer or cystic fibrosis. CAD, 2018 Canadian dollars. In 2018, $1 CAD in 2018 = $0.77 US dollars.
Page created: July 10, 2020
Page updated: August 18, 2020
Page reviewed: August 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.